Pharmacology, Toxicology and Pharmaceutical Science
Glioblastoma
100%
Bevacizumab
78%
Neoplasm
60%
Irinotecan
42%
Solid Malignant Neoplasm
36%
Biological Marker
33%
Chemotherapy
31%
Overall Survival
29%
Small Cell Lung Cancer
28%
Pharmacokinetic
26%
Epidermal Growth Factor Receptor
26%
Diseases
24%
Malignant Neoplasm
22%
Monoclonal Antibody
21%
Progression Free Survival
20%
Phase II Trials
19%
Adverse Event
19%
Cetuximab
18%
Vasculotropin
17%
Combination Therapy
17%
Temozolomide
17%
Maximum Tolerated Dose
15%
Keyphrases
Bevacizumab
78%
Irinotecan
42%
Tumor
38%
Glioblastoma multiforme
38%
Solid Tumors
32%
Small Cell Lung Cancer
28%
Cetuximab
28%
Positron Emission Tomography
28%
Chemotherapy
27%
Glioblastoma
27%
Monoclonal Antibody
26%
Pharmacokinetics
25%
Dose-escalation Study
24%
Epidermal Growth Factor Receptor
23%
Overall Survival
22%
Recurrent Glioblastoma multiforme
22%
Combination Therapy
21%
Advanced Solid Tumors
20%
Phase I Study
20%
Non-small Cell Lung Cancer (NSCLC)
20%
Radiotherapy
18%
Monotherapy
18%
Phase II Study
17%
Clinical Activity
16%
Maximum Tolerated Dose
15%
Lung Cancer Staging
15%
Medicine and Dentistry
Glioblastoma
37%
positron emission tomographic scan
37%
Neoplasm
36%
Small Cell Lung Cancer
33%
Lung Cancer
20%
Bevacizumab
18%
Non Small Cell Lung Cancer
18%
Diseases
16%
Fluorine-18
16%